Reimbursed Care Access in Liechtenstein

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Esketamine nasal spray (Spravato) received a centralised marketing authorisation valid across the EU/EEA on 18 December 2019; the European public assessment reports and product information describe its authorised indication for adults with treatment‑resistant major depressive disorder and specify supervised clinic administration and restricted distribution procedures. #

Because Liechtenstein participates in the European Economic Area and regulatory decisions from the European Medicines Agency (centralised authorisations) apply across the EEA, esketamine may be placed on the market for clinical use in Liechtenstein under the EMA centralised authorisation framework. Actual patient access and reimbursement for esketamine in Liechtenstein are determined by the country’s statutory health insurance and local coverage/prior‑authorisation rules; clinicians must follow the product’s restricted distribution and administration requirements (clinic supervision, blood‑pressure monitoring, and post‑administration observation) as set out in the EMA product documents. #

Providers or patients seeking reimbursement information should consult the patient’s statutory insurer or the Liechtenstein health authorities for the specific reimbursement rules and any prior‑authorisation requirements, as national coverage decisions (price negotiation, inclusion on reimbursable lists, and prior‑authorisation protocols) are made at the national level despite the centralised marketing authorisation.

Ketamine (racemic ketamine) is used in medical practice for anaesthesia and—in many countries—as off‑label treatment (e.g., IV ketamine infusions) for treatment‑resistant depression in specialised clinics; where used for psychiatric indications this is typically off‑label and governed by local medical practice rules. In Liechtenstein there is no publicly documented national authorised, reimbursed psychiatric ketamine‑infusion program distinct from the centrally authorised esketamine product; off‑label ketamine use (for anaesthesia or in experimental/individual therapeutic contexts) would be handled under standard medical practice and by the national statutory health insurance’s rules on reimbursement for off‑label or hospital‑administered therapies. Clinicians employing off‑label ketamine for psychiatric indications must follow applicable professional regulations and secure payer authorisation when seeking reimbursement.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.